Entos lures former Plexxikon CEO to guide push toward the clinic; Ex-Bristol Myers immunology chief finds new home
Around the same time that Entos CEO Tom Miller realized it was time to bring on a CSO to guide the company’s cancer drugs into the clinic, Daiichi Sankyo was winding down operations at its longtime subsidiary Plexxikon.
That led Miller to find Chao Zhang — Plexxikon’s former CEO who “couldn’t have been more tailor-made for driving our drug development program,” Miller said.
Zhang started at Entos earlier this week, after wrapping up a nearly 21-year career at Plexxikon.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,300+ biopharma pros reading Endpoints daily — and it's free.